BioSpace News Archive

Editas Medicine, Inc., a leading genome editing company, announced the grant of inducement awards to the Company’s newly appointed Chief Financial Officer, Michelle Robertson.

The Dental Solutions Company, announced it will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 in San Francisco..

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00 am GMT from a Phase 2b dose-ranging study evaluating nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe COPD.

Three-Day Event Will Galvanize Thought Leaders, Researchers and Community Members Around Topics That Will Change the Culture and Reality of Paralysis

Wayne State University President M. Roy Wilson announced the appointment of Mark Schweitzer, M.D., as dean of the university’s School of Medicine and vice president of Health Affairs for the university..

VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering and improving the healthcare economics, is pleased to announce it will be presenting at Biotech Showcase 2020.

Alydia Health, a clinical-stage medical device company developing an innovative technology to prevent maternal morbidity and mortality caused by abnormal postpartum bleeding and hemorrhage, today announced that Erica Rogers has been appointed to the company’s board of directors as a strategic advisor.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a strategic outlook for 2020 outlining key priorities for its broad pipeline.

The Finnish medical technology company Planmed Oy and the UK-based medical X-ray software solutions provider IBEX Innovations Ltd. have signed a collaboration agreement

Novus Therapeutics, Inc. announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate of 5,605,816 shares of common stock having an exercise price of $4.00 issued by the company on May 2, 2019, at a reduced exercise price of $0.84 per share.